SGLT2 Inhibitors Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | AstraZeneca, Boehringer Ingelheim, Eli Lilly, TheracosBio, Janssen, Pfizer, Merck

SGLT2 Inhibitors Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | AstraZeneca, Boehringer Ingelheim, Eli Lilly, TheracosBio, Janssen, Pfizer, Merck

“DelveInsight Business Research LLP”
The SGLT2 Inhibitors market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to necessitate extensive clinical trials to establish both safety and efficacy.

DelveInsight’s SGLT2 Inhibitors Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market shares, and the projected market size for SGLT2 Inhibitors from 2019 to 2032. The market analysis is segmented across the 7MM, encompassing the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

SGLT2 Inhibitors Overview

SGLT2 inhibitors, short for sodium-glucose co-transporter 2 inhibitors, are a class of oral antidiabetic medications designed to lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys. These drugs act specifically on the SGLT2 transporter located in the proximal renal tubules, thereby preventing the reabsorption of glucose from the urine back into the bloodstream. By increasing urinary glucose excretion, SGLT2 inhibitors promote glycosuria and lower blood glucose levels, leading to improved glycemic control in patients with diabetes.

Mechanism of Action of SGLT2 Inhibitors

The mechanism of action of SGLT2 inhibitors revolves around their selective inhibition of the SGLT2 transporter in the kidneys. Under normal physiological conditions, the SGLT2 transporter is responsible for reabsorbing approximately 90% of filtered glucose from the urine back into the bloodstream. However, in patients with diabetes, this mechanism becomes dysregulated, resulting in excessive glucose reabsorption and hyperglycemia.

SGLT2 inhibitors work by binding to and blocking the SGLT2 transporter, thereby preventing the reabsorption of glucose from the urine into the bloodstream. This leads to increased urinary glucose excretion and reduced plasma glucose levels, ultimately improving glycemic control in patients with diabetes. Additionally, SGLT2 inhibitors have been shown to promote weight loss and lower blood pressure, making them attractive therapeutic options for patients with comorbidities such as obesity and hypertension.

SGLT2 Inhibitors Applications for Diseases

SGLT2 inhibitors have demonstrated efficacy across various diseases, with their primary indication being the management of type 2 diabetes mellitus. Some notable applications include:

  • Type 2 Diabetes Mellitus (T2DM): SGLT2 inhibitors are widely used as adjunctive therapy in the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. These drugs offer several advantages, including potent glucose-lowering efficacy, weight loss benefits, and a low risk of hypoglycemia, making them suitable for a broad range of patients with diabetes.
  • Heart Failure: SGLT2 inhibitors have shown promising results in the treatment of heart failure, particularly in patients with heart failure with reduced ejection fraction (HFrEF). These drugs have been shown to reduce the risk of heart failure hospitalization and cardiovascular mortality, independent of their glucose-lowering effects, making them valuable additions to the armamentarium for heart failure management.
  • Chronic Kidney Disease (CKD): SGLT2 inhibitors have emerged as potential renoprotective agents in patients with chronic kidney disease, particularly those with diabetes. These drugs have been shown to reduce the risk of kidney failure, slow the decline in kidney function, and decrease albuminuria, offering new therapeutic options for patients with diabetic kidney disease and other forms of CKD.
  • Non-Alcoholic Fatty Liver Disease (NAFLD): SGLT2 inhibitors are being investigated for their potential role in the management of non-alcoholic fatty liver disease, a common comorbidity of type 2 diabetes mellitus. These drugs have shown promise in reducing hepatic fat accumulation, improving liver function tests, and decreasing markers of liver inflammation and fibrosis, suggesting potential benefits in patients with NAFLD.

SGLT2 Inhibitors Market Outlook and Future Perspectives

The market outlook for SGLT2 inhibitors is highly promising, driven by the growing prevalence of diabetes and the expanding therapeutic applications of these drugs across various diseases. Key factors contributing to the market growth include:

  • Clinical Success: The increasing clinical evidence supporting the efficacy and safety of SGLT2 inhibitors in the management of diabetes, heart failure, chronic kidney disease, and other conditions has fueled their widespread adoption and integration into clinical practice guidelines. With numerous clinical trials demonstrating significant benefits in terms of cardiovascular and renal outcomes, the market for SGLT2 inhibitors is poised for substantial growth.
  • Expanding Indications: The exploration of new therapeutic indications for SGLT2 inhibitors beyond diabetes, such as heart failure and chronic kidney disease, is expanding the market opportunities and driving further adoption of these drugs in clinical practice. As ongoing research elucidates the pleiotropic effects of SGLT2 inhibitors on various organ systems, the therapeutic potential of these drugs continues to evolve, offering new avenues for improving patient outcomes and reducing the burden of chronic diseases.
  • Combination Therapies: The development of combination therapies incorporating SGLT2 inhibitors with other antidiabetic agents, cardiovascular drugs, and renoprotective agents is further expanding the therapeutic landscape and offering synergistic benefits in the management of complex disease states. By leveraging the complementary mechanisms of action of different drug classes, combination therapies have the potential to enhance therapeutic efficacy, improve treatment adherence, and optimize patient outcomes.
  • Patient-Centric Care: The patient-centric nature of SGLT2 inhibitors, characterized by their favorable safety profile, convenient dosing regimens, and potential for weight loss and cardiovascular benefits, positions them as attractive therapeutic options for patients with diabetes and related comorbidities. As healthcare systems increasingly prioritize value-based care and patient-centered outcomes, SGLT2 inhibitors are poised to play a central role in the management of chronic diseases, offering holistic approaches to improving patient health and quality of life.

Looking ahead, the future of SGLT2 inhibitors appears promising, with continued research and innovation expected to further optimize treatment approaches and expand the therapeutic opportunities for patients with diabetes and related conditions. As the field of diabetes management continues to evolve, SGLT2 inhibitors are poised to remain at the forefront of innovation, offering transformative solutions for improving glycemic control, cardiovascular health, and renal outcomes in patients with diabetes and beyond.

Key SGLT2 Inhibitors Therapies and Companies

  • FARXIGA/FORXIGA – AstraZeneca
  • JARDIANCE – Boehringer Ingelheim, Eli Lilly
  • BRENZAVVY – TheracosBio
  • INVOKANA – Janssen
  • STEGLATRO – Pfizer, Merck & Co.

And Many Others

Discover More about the FDA-Approved SGLT2 Inhibitors:

Key Takeaways from the SGLT2 Inhibitors Market Report

  • According to DelveInsight’s analysis, the SGLT2 Inhibitors market is expected to exhibit substantial growth, with a significant Compound Annual Growth Rate (CAGR) projected by 2032.
  • Prominent companies in the SGLT2 Inhibitors sector, including AstraZeneca, Boehringer Ingelheim, Eli Lilly, TheracosBio, Janssen, Pfizer, Merck & Co., are actively pioneering the development of innovative SGLT2 Inhibitors, with potential market availability anticipated in the forthcoming years.
  • Some notable SGLT2 Inhibitors include FARXIGA/FORXIGA, JARDIANCE, BRENZAVVY, INVOKANA, STEGLATRO, alongside others in the market.

SGLT2 Inhibitors Market Dynamics

The landscape of the SGLT2 Inhibitors market is poised for transformation in the foreseeable future. With a burgeoning drug pipeline, SGLT2 Inhibitors presents a promising opportunity for major corporations to bolster their market presence significantly. This is particularly evident in the emergence of diverse and robust pipelines, which offer ample potential for growth and market expansion.

Moreover, ongoing research is exploring numerous potential therapies aimed at addressing SGLT2 Inhibitors, underscoring the anticipation of substantial influence on the market throughout the projected period. Additionally, the impending debut of novel therapies boasting enhanced efficacy, coupled with advancements in diagnosis rates, is poised to fuel the expansion of the SGLT2 Inhibitors market across the 7MM (Seven Major Markets).

Additionally, the trajectory of growth in the SGLT2 Inhibitors market could encounter impediments such as setbacks and discontinuation of promising therapies, challenges related to affordability, market access, and reimbursement hurdles, as well as a scarcity of healthcare professionals with specialized expertise in this domain.

Scope of the SGLT2 Inhibitors Market Report

  • The report includes key event summaries, an overview of the target patient demographics, epidemiological projections, market forecasts, insights into patient pathways, and diverse biomarker testing rates.
  • Furthermore, the report provides comprehensive coverage of current and emerging therapies, including insights on the addressable patient population for SGLT2 Inhibitors.
  • The report includes an in-depth examination of the SGLT2 Inhibitors market, covering historical and projected market size, therapy market shares, detailed assumptions, and the rationale behind our analytical approach.
  • The report offers a strategic advantage in business planning by leveraging SWOT analysis, expert insights, and input from key opinion leaders (KOLs) to understand market trends and treatment preferences, thereby influencing and propelling the growth of SGLT2 Inhibitors.

Explore Further About SGLT2 Inhibitors Drugs in Development at:

Table of Contents

1. SGLT2 Inhibitors Market Key Insights

2. SGLT2 Inhibitors Market Report Introduction

3. SGLT2 Inhibitors Market Overview at a Glance

4. SGLT2 Inhibitors Market Executive Summary

5. Disease Background and Overview

6. SGLT2 Inhibitors Treatment and Management

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed SGLT2 Inhibitors 

10. Emerging SGLT2 Inhibitors 

11. SGLT2 Inhibitors Market Analysis (Across 7MM)

12. SGLT2 Inhibitors Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

To Gain Deeper Insights into the Scope of the Reports and Their Key Coverage Areas, Download the Sample PDF:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Other Trending Reports By DelveInsight

Contrast-Induced Nephropathy Market

“Contrast-Induced Nephropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Contrast-Induced Nephropathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Contrast-Induced Nephropathy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States